High	high	O	O
dose	dose	O	O
dexmedetomidine	dexmedetomidine	O	O
as	as	O	O
the	the	O	O
sole	sole	O	O
sedative	sedative	O	O
for	for	O	O
pediatric	pediatric	O	O
MRI.OBJECTIVE	mri.objective	O	O
:	:	O	O
This	this	O	O
large-scale	large-scale	O	O
retrospective	retrospective	O	O
review	review	O	O
evaluates	evaluates	O	O
the	the	O	O
sedation	sedation	O	O
profile	profile	O	O
of	of	O	O
dexmedetomidine	dexmedetomidine	O	O
.	.	O	O

AIM	aim	O	O
:	:	O	O
To	to	O	O
determine	determine	O	O
the	the	O	O
hemodynamic	hemodynamic	O	O
responses	responses	O	O
,	,	O	O
efficacy	efficacy	O	O
and	and	O	O
adverse	adverse	O	O
events	events	O	O
associated	associated	O	O
with	with	O	O
the	the	O	O
use	use	O	O
of	of	O	O
high	high	O	O
dose	dose	O	O
dexmedetomidine	dexmedetomidine	O	O
as	as	O	O
the	the	O	O
sole	sole	O	O
sedative	sedative	O	O
for	for	O	O
magnetic	magnetic	O	O
resonance	resonance	O	O
imaging	imaging	O	O
(	(	O	O
MRI	mri	O	O
)	)	O	O
studies	studies	O	O
.	.	O	O

BACKGROUND	background	O	O
:	:	O	O
Dexmedetomidine	dexmedetomidine	O	O
has	has	O	O
been	been	O	O
used	used	O	O
at	at	O	O
our	our	O	O
institution	institution	O	O
since	since	O	O
2005	2005	O	O
to	to	O	O
provide	provide	O	O
sedation	sedation	O	O
for	for	O	O
pediatric	pediatric	O	O
radiological	radiological	O	O
imaging	imaging	O	O
studies	studies	O	O
.	.	O	O

Over	over	O	O
time	time	O	O
,	,	O	O
an	an	O	O
effective	effective	O	O
protocol	protocol	O	O
utilizing	utilizing	O	O
high	high	O	O
dose	dose	O	O
dexmedetomidine	dexmedetomidine	O	O
as	as	O	O
the	the	O	O
sole	sole	O	O
sedative	sedative	O	O
agent	agent	O	O
has	has	O	O
evolved	evolved	O	O
.	.	O	O

METHODS/MATERIALS	methods/materials	O	O
:	:	O	O
As	as	O	O
part	part	O	O
of	of	O	O
the	the	O	O
ongoing	ongoing	O	O
Quality	quality	O	O
Assurance	assurance	O	O
process	process	O	O
,	,	O	O
data	data	O	O
on	on	O	O
all	all	O	O
sedations	sedations	O	O
are	are	O	O
reviewed	reviewed	O	O
monthly	monthly	O	O
and	and	O	O
protocols	protocols	O	O
modified	modified	O	O
as	as	O	O
needed	needed	O	O
.	.	O	O

Data	data	O	O
were	were	O	O
analyzed	analyzed	O	O
from	from	O	O
all	all	O	O
747	747	O	O
consecutive	consecutive	O	O
patients	patients	O	O
who	who	O	O
received	received	O	O
dexmedetomidine	dexmedetomidine	O	O
for	for	O	O
MRI	mri	O	O
sedation	sedation	O	O
from	from	O	O
April	april	O	O
2005	2005	O	O
to	to	O	O
April	april	O	O
2007	2007	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
Since	since	O	O
2005	2005	O	O
,	,	O	O
the	the	O	O
10-min	10-min	O	O
loading	loading	O	O
dose	dose	O	O
of	of	O	O
our	our	O	O
dexmedetomidine	dexmedetomidine	O	O
protocol	protocol	O	O
increased	increased	O	O
from	from	O	O
2	2	O	O
to	to	O	O
3	3	O	O
microg.kg(-1	microg.kg(-1	O	O
)	)	O	O
,	,	O	O
and	and	O	O
the	the	O	O
infusion	infusion	O	O
rate	rate	O	O
increased	increased	O	O
from	from	O	O
1	1	O	O
to	to	O	O
1.5	1.5	O	O
to	to	O	O
2	2	O	O
microg.kg(-1).h(-1	microg.kg(-1).h(-1	O	O
)	)	O	O
.	.	O	O

The	the	O	O
current	current	O	O
sedation	sedation	O	O
protocol	protocol	O	O
progressively	progressively	O	O
increased	increased	O	O
the	the	O	O
rate	rate	O	O
of	of	O	O
successful	successful	O	O
sedation	sedation	O	O
(	(	O	O
able	able	O	O
to	to	O	O
complete	complete	O	O
the	the	O	O
imaging	imaging	O	O
study	study	O	O
)	)	O	O
when	when	O	O
using	using	O	O
dexmedetomidine	dexmedetomidine	O	O
alone	alone	O	O
from	from	O	O
91.8	91.8	O	O
%	%	O	O
to	to	O	O
97.6	97.6	O	O
%	%	O	O
(	(	O	O
P	p	O	O
=	=	O	O
0.009	0.009	O	O
)	)	O	O
,	,	O	O
reducing	reducing	O	O
the	the	O	O
requirement	requirement	O	O
for	for	O	O
adjuvant	adjuvant	O	O
pentobarbital	pentobarbital	S_chemical	O
in	in	O	O
the	the	O	O
event	event	O	O
of	of	O	O
sedation	sedation	O	O
failure	failure	O	O
with	with	O	O
dexmedetomidine	dexmedetomidine	O	O
alone	alone	O	O
and	and	O	O
decreased	decreased	O	O
the	the	O	O
mean	mean	O	O
recovery	recovery	O	O
time	time	O	O
by	by	O	O
10	10	O	O
min	min	O	O
(	(	O	O
P	p	O	O
<	<	O	O
0.001	0.001	O	O
)	)	O	O
.	.	O	O

Although	although	O	O
dexmedetomidine	dexmedetomidine	O	O
sedation	sedation	O	O
was	was	O	O
associated	associated	O	O
with	with	O	O
a	a	O	O
16	16	O	O
%	%	O	O
incidence	incidence	O	O
of	of	O	O
bradycardia	bradycardia	O	S_disease
,	,	O	O
all	all	O	O
concomitant	concomitant	O	O
mean	mean	O	O
arterial	arterial	O	O
blood	blood	O	O
pressures	pressures	O	O
were	were	O	O
within	within	O	O
20	20	O	O
%	%	O	O
of	of	O	O
age-adjusted	age-adjusted	O	O
normal	normal	O	O
range	range	O	O
and	and	O	O
oxygen	oxygen	S_chemical	O
saturations	saturations	O	O
were	were	O	O
95	95	O	O
%	%	O	O
or	or	O	O
higher	higher	O	O
.	.	O	O

CONCLUSION	conclusion	O	O
:	:	O	O
Dexmedetomidine	dexmedetomidine	O	O
in	in	O	O
high	high	O	O
doses	doses	O	O
provides	provides	O	O
adequate	adequate	O	O
sedation	sedation	O	O
for	for	O	O
pediatric	pediatric	O	O
MRI	mri	O	O
studies	studies	O	O
.	.	O	O

While	while	O	O
use	use	O	O
of	of	O	O
high	high	O	O
dose	dose	O	O
dexmedetomidine	dexmedetomidine	O	O
is	is	O	O
associated	associated	O	O
with	with	O	O
decreases	decreases	O	O
in	in	O	O
heart	heart	O	O
rate	rate	O	O
and	and	O	O
blood	blood	O	O
pressure	pressure	O	O
outside	outside	O	O
the	the	O	O
established	established	O	O
'	'	O	O
awake	awake	O	O
'	'	O	O
norms	norms	O	O
,	,	O	O
this	this	O	O
deviation	deviation	O	O
is	is	O	O
generally	generally	O	O
within	within	O	O
20	20	O	O
%	%	O	O
of	of	O	O
norms	norms	O	O
,	,	O	O
and	and	O	O
is	is	O	O
not	not	O	O
associated	associated	O	O
with	with	O	O
adverse	adverse	O	O
sequelae	sequelae	O	O
.	.	O	O

Dexmedetomidine	dexmedetomidine	O	O
is	is	O	O
useful	useful	O	O
as	as	O	O
the	the	O	O
sole	sole	O	O
sedative	sedative	O	O
for	for	O	O
pediatric	pediatric	O	O
MRI	mri	O	O
.	.	O	O

